Santiago Jose A, Potashkin Judith A
NeuroHub Analytics, LLC, Chicago, IL, United States.
Cellular and Molecular Pharmacology Department, Center for Neurodegenerative Diseases and Therapeutics, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, United States.
Front Aging Neurosci. 2021 Feb 12;13:631770. doi: 10.3389/fnagi.2021.631770. eCollection 2021.
A wide range of comorbid diseases is associated with Alzheimer's disease (AD), the most common neurodegenerative disease worldwide. Evidence from clinical and molecular studies suggest that chronic diseases, including diabetes, cardiovascular disease, depression, and inflammatory bowel disease, may be associated with an increased risk of AD in different populations. Disruption in several shared biological pathways has been proposed as the underlying mechanism for the association between AD and these comorbidities. Notably, inflammation is a common dysregulated pathway shared by most of the comorbidities associated with AD. Some drugs commonly prescribed to patients with diabetes and cardiovascular disease have shown promising results in AD patients. Systems-based biology studies have identified common genetic factors and dysregulated pathways that may explain the relationship of comorbid disorders in AD. Nonetheless, the precise mechanisms for the occurrence of disease comorbidities in AD are not entirely understood. Here, we discuss the impact of the most common comorbidities in the clinical management of AD patients.
多种共病与阿尔茨海默病（AD）相关，AD是全球最常见的神经退行性疾病。临床和分子研究证据表明，包括糖尿病、心血管疾病、抑郁症和炎症性肠病在内的慢性疾病，可能在不同人群中与AD风险增加相关。几种共享生物途径的破坏已被提出作为AD与这些共病之间关联的潜在机制。值得注意的是，炎症是大多数与AD相关的共病所共有的一个常见失调途径。一些通常开给糖尿病和心血管疾病患者的药物在AD患者中已显示出有前景的结果。基于系统的生物学研究已经确定了可能解释AD中共病关系的常见遗传因素和失调途径。尽管如此，AD中疾病共病发生的确切机制尚未完全了解。在此，我们讨论最常见共病对AD患者临床管理的影响。
